Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Sertindole in schizophrenia: efficacy and safety issues.

Authors
Type
Published Article
Journal
Expert Opinion on Pharmacotherapy
1744-7666
Publisher
Informa UK (Taylor & Francis)
Publication Date
Volume
15
Issue
13
Pages
1943–1953
Identifiers
DOI: 10.1517/14656566.2014.947960
PMID: 25084209
Source
Medline
Keywords
License
Unknown

Abstract

The reviewed studies suggest a beneficial effect of sertindole on positive, negative and cognitive symptoms, and on relapse prevention. Although generally well tolerated, sertindole is associated with a dose-related QT-interval prolongation; thus, its administration requires electrocardiogram screening and monitoring. The presence of congenital long QT syndrome, prolongated QTc at baseline, cardiac disease and drug interactions should be carefully considered before prescribing sertindole. Further direct 'head-to-head' comparisons with other second-generation antipsychotics (SGAs), trials on special populations and further clarification on cardiac safety are needed to better define the role of sertindole in the treatment of schizophrenia.

Statistics

Seen <100 times